← Back to Previous Page

 

S088: PITUITARY APOPLEXY IN ACROMEGALY: UNDERSTANDING SPONTANEOUS REMISSION, RELAPSE, AND MANAGEMENT
S Macon¹; M Wierzbicki¹; C Christman¹; Z Hasana²; R Murayi, MD³; R Feng, MD, MS³; J J Evans, MD³; ¹Sidney Kimmel Medical College, Thomas Jefferson University; ²Philadelphia College of Osteopathic Medicine; ³Department of Neurosurgery, Thomas Jefferson University

Introduction: While transsphenoidal surgery is the primary treatment for acromegaly, spontaneous biochemical remission due to pituitary apoplexy is a rare phenomenon. Limited data exist in the literature regarding its frequency, durability, and underlying mechanisms. This study aims to characterize this clinical course and contribute to its sparse existing understanding.

Objective: To evaluate pooled biochemical remission rates in acromegalic patients who experience apoplexy and assess clinical, radiographic, and treatment factors that are predictive of time to remission and relapse rates.

Methods: A systematic review with individual patient-level analysis was conducted via PubMed to identify studies reporting cases of acromegaly complicated by pituitary apoplexy. Data extracted included clinical presentation, imaging characteristics, treatment strategy, and long-term outcomes. Pooled remission rates were calculated. Kaplan-Meier analysis assessed time to remission, and multivariate logistic regression was used to identify predictors of relapse.

Results: 54 studies met inclusion criteria, yielding 82 unique patients. The combined pooled biochemical remission rate following apoplexy was 74.7%. Specifically, there was a 74.3% remission rate after surgical intervention and 75% with non-operative management (p = 1.0). Surgery was the only significant predictor of biochemical relapse (p = 0.048). Time to remission was not affected by surgery or other clinical or radiographic features. Suprasellar and cavernous sinus invasion, visual changes, nausea/vomiting, seizures, age, and sex were not associated with relapse. Early preliminary analyses suggested potential associations with suprasellar invasion and visual symptoms with relapse; however, these did not remain significant with expanded data and thorough review. 

Conclusion: Pituitary apoplexy represents a unique biological event capable of inducing biochemical remission in acromegaly independent of surgery, clinical presentation, or radiographic features. In this analysis, surgery was the only predictor of relapse, although overall remission rates remained high across treatment groups. This may reflect selection bias, with surgery potentially indicating underlying disease severity rather than operative failure. These results underscore the curative potential of apoplexy and suggest that careful surveillance rather than routine surgical intervention may be appropriate in select patients. However, surgery continues to be indispensable for patients with visual deficits or mass effect. Future studies are needed to validate these findings, define risk stratification strategies, and explore the biological and clinical factors that differentiate infarction-driven remission from surgical outcomes.

 

← Back to Previous Page